Dynavax Technologies Co. (NASDAQ:DVAX) insider David F. Novack sold 34,214 shares of the company’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $16.52, for a total value of $565,215.28. Following the completion of the transaction, the insider now owns 21,613 shares of the company’s stock, valued at $357,046.76. The transaction was disclosed in a filing with the SEC, which is available at this link.
DVAX opened at $18.55 on Friday. The company has a market cap of $1,196.61, a price-to-earnings ratio of -10.72 and a beta of 0.84. Dynavax Technologies Co. has a one year low of $5.05 and a one year high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, March 8th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.32). Dynavax Technologies had a negative return on equity of 57.43% and a negative net margin of 29,099.08%. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.53 million. equities research analysts forecast that Dynavax Technologies Co. will post -1.91 earnings per share for the current fiscal year.
Several large investors have recently made changes to their positions in the company. Royal Bank of Canada raised its position in shares of Dynavax Technologies by 17.0% in the 2nd quarter. Royal Bank of Canada now owns 20,454 shares of the biopharmaceutical company’s stock worth $198,000 after acquiring an additional 2,975 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in Dynavax Technologies by 13.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 30,755 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 3,604 shares in the last quarter. Voya Investment Management LLC increased its position in Dynavax Technologies by 26.3% during the 2nd quarter. Voya Investment Management LLC now owns 21,403 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 4,462 shares in the last quarter. Legal & General Group Plc increased its position in Dynavax Technologies by 36.1% during the 3rd quarter. Legal & General Group Plc now owns 17,013 shares of the biopharmaceutical company’s stock valued at $365,000 after buying an additional 4,512 shares in the last quarter. Finally, Vident Investment Advisory LLC increased its position in Dynavax Technologies by 3.1% during the 3rd quarter. Vident Investment Advisory LLC now owns 150,258 shares of the biopharmaceutical company’s stock valued at $3,231,000 after buying an additional 4,553 shares in the last quarter. 71.22% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts recently weighed in on DVAX shares. Royal Bank of Canada restated a “buy” rating and set a $25.00 target price on shares of Dynavax Technologies in a report on Friday, March 9th. BidaskClub upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, March 27th. Cantor Fitzgerald restated an “overweight” rating and set a $27.00 target price (up from $25.00) on shares of Dynavax Technologies in a report on Thursday, March 8th. Zacks Investment Research cut Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, JPMorgan Chase lowered Dynavax Technologies from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $31.00 to $25.00 in a research report on Wednesday, February 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.67.
WARNING: “David F. Novack Sells 34,214 Shares of Dynavax Technologies Co. (NASDAQ:DVAX) Stock” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/dynavax-technologies-co-dvax-insider-david-f-novack-sells-34214-shares.html.
About Dynavax Technologies
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.